Table 6 Non-relapse mortality cumulative incidence, relapse incidence, progression-free survival (GvHD-free relapse-free survival and overall survival.

Total

[2000–2022]

35

18 [7.1–32.8]

15.9 [5.6–30.9]

66.1 [47–79.7]

50 [30.6–66.7]

71.1 [51.4–84]

Year of HCT

[2000–2007]

16 (45.7)

25 [7.2–48.1]

25 [7.2–48.2]

50 [24.5–71]

41.7 [17.4–64.5]

56.2 [29.5–76.2]

[2008–2022]

19 (54.3)

10.5 [1.7–29]

5.3 [0.3–22.1]

84.2 [58.7–94.6]

62.3 [34–81.3]

89.5 [64.1–97.3]

P value

0.37

0.18

0.09

0.58

0.09

Age at HCT

(0–6)

19 (54.3)

12.8 [1.8–34.8]

12.1 [1.8–33.2]

75.1 [45.6–90.1]

63 [30.9–83.4]

79.5 [48.1–93.1]

[7–18)

16 (45.7)

25 [7.3–48]

18.8 [4.2–41.3]

56.2 [29.5–76.2]

37.5 [15.4–59.8]

61.1 [32.7–80.5]

P value

0.3

0.66

0.21

0.053

0.22

Recipient sex

Male

23 (65.7)

25 [7.2–48.1]

20.6 [5.9–41.4]

55.6 [31.1–74.4]

40.9 [18.5–62.3]

63.9 [37.9–81.3]

Female

12 (34.3)

10.5 [1.7–29]

8.3 [0.4–32.4]

83.3 [48.2–95.6]

66.7 [33.7–86]

83.3 [48.2–95.6]

P value

0.37

0.35

0.12

0.24

0.28

Months between diagnosis and HCT

[1–8)

19 (54.3)

16.8 [3.9–37.6]

17.5 [4–38.9]

65.7 [38.8–83]

52.7 [26.7–73.3]

71.3 [44.1–87]

[9–136]

16 (45.7)

18.8 [4.3–41.1]

13.8 [2–36.7]

67.5 [38.4–85.1]

48.2 [20.8–71.2]

72.7 [42–88.9]

P value

0.78

0.84

0.87

0.49

0.86

Donor type

MSD

17 (48.6)

12.6 [1.9–34.1]

13 [1.9–34.9]

74.3 [45–89.6]

67 [37.9–84.7]

73.7 [43.9–89.3]

Other

18 (51.4)

22.2 [6.6–43.6]

18.9 [4.1–41.9]

58.8 [32–78.1]

34.9 [12.4–58.8]

69.3 [40.6–86.2]

P value

0.42

0.56

0.24

0.07

0.6

Source of HCs

BM

15 (42.9)

0%

14.9 [2.2–38.9]

85.1 [52.3–96.1]

70.1 [38.5–87.6]

90.9 [50.8–98.7]

Other

20 (57.1)

32 [12.3–53.9]

17.1 [3.8–38.5]

50.8 [26.3–71]

36.1 [14.5–58.4]

54 [28.1–74.2]

P value

0.02

0.81

0.03

0.09

0.01